Introduction
============

Uveitis is a leading cause of visual morbidity and causes approximately 30,000 new cases of legal blindness annually in the United States alone.[@b1-opth-9-889],[@b2-opth-9-889] Because uveitis encompasses many heterogeneous disorders, factors that vary regionally, such as age, sex, ethnicity, environmental exposures, and genetics, influence ocular inflammation in ways that are incompletely understood.[@b3-opth-9-889],[@b4-opth-9-889]

Worldwide, epidemiologic reports on uveitis have led to the identification of new entities, contributed to monitoring of shifting patterns of uveitis, and guided diagnostic and therapeutic approaches.[@b5-opth-9-889]--[@b12-opth-9-889] Infectious uveitides, for example, are strongly associated with geography (ie, toxoplasmosis in Brazil, onchocerciasis in Africa, and histoplasmosis in the Ohio River Valley).[@b6-opth-9-889] In the United States, there has been increasing interest in population-based studies of uveitis, with growing recognition that demographics and regional factors affect presentation, management, and outcomes ([Figure 1](#f1-opth-9-889){ref-type="fig"}).[@b5-opth-9-889],[@b9-opth-9-889]--[@b11-opth-9-889] To date, no such reports exist for the mid-Atlantic United States.

This is a retrospective review of the epidemiologic features of all patients seen with uveitis over a 30-year period at the University of Virginia (UVA), a tertiary referral center for a racially diverse population, attracting patients from Virginia (VA) and neighboring states.

Methods
=======

Following Institutional Review Board approval, a retrospective review was performed of 1,238 patients seen at UVA from 1984 to 2014 with uveitis identified by 2010 International Classification of Disease, 9th revision (ICD-9) codes corresponding to ocular inflammatory conditions. Individual charts were reviewed, and 747 patients were excluded because a diagnosis of uveitis meeting International Uveitis Study Group criteria could not be confirmed by an attending physician (AKR).[@b13-opth-9-889] Owing to the long-term nature of this study and reliance on paper records, not all data was available on all patients. To improve our ability to compare our findings with those of nearby centers, patients with scleritis and episcleritis without intraocular inflammation were also excluded.[@b5-opth-9-889] However, we included cases of cytomegalovirus (CMV) uveitis.

Demographic data, including age, sex, ethnicity, payer status, duration of follow up, number of eye clinic visits, and postal code of residence were recorded. Complete ophthalmic examination findings including best corrected visual acuity, pupillary response, slit-lamp examination, intraocular pressure, and fundoscopic exam were also recorded. Optical coherence tomography, fluorescein angiography, automated perimetry, and other ancillary tests, including serology, radiology, microbiology, and biopsy, were performed when appropriate. Intraocular infection was confirmed with fluid sampling or biopsy, for microscopy, cytology, and culture, or polymerase chain reaction, when appropriate. Post-procedural uveitis was defined as ocular inflammation following intraocular surgery, laser, or intravitreal injection. The term undifferentiated uveitis was applied if intraocular inflammation could not be attributed to a recognized uveitic entity.

Uveitis was classified by anatomic involvement as either anterior, intermediate, posterior, or panuveitis as per Standardized Uveitis Nomenclature (SUN) criteria.[@b14-opth-9-889] SUN criteria were also used to describe the uveitis as unilateral or bilateral and acute or insidious. Details of management, including the use of local and systemic steroids, antihypertensive drops, intravitreal injections, sub-Tenon injections, antimetabolites, anti-tumor necrosis factor (TNF) agents, cataract extraction, pars plana vitrectomy, and glaucoma management were recorded. Mild visual loss was defined as \>20/50 (logMAR\<0.4) Snellen visual acuity, moderate visual loss as 20/50--20/200 (logMAR 0.4 to \<1.0), and severe visual loss as \<20/200 (logMAR ≥1.0).

Statistical analysis
--------------------

Statistical analyses were performed using Statistical Analysis System (SAS) for OS/2, version 9.3 (SAS Institute, Inc., Cary, NC, USA). Chi-square test, Fisher's exact test, *t*-test, and logistic regression analysis were used to test differences between groups, when appropriate. Statistical significance was defined as *P*-value less than 0.05.

Results
=======

A total 491 of patients (644 eyes) were included in this study. The mean duration of follow up was 4.8 years (±6.8 years). The mean number of ophthalmic visits was eleven (±14.3). Of 491 patients, 153 (31.2%) had bilateral disease, while 338 (68.8%) had unilateral disease. For those with unilateral disease, the right eye was involved in 178 patients (52.7%). Of 491 patients, 57 (11.6%) had acute onset and 158 (32.8%) had insidious disease. A total 276 (56.2%) patients had chronic uveitis.

Age
---

The mean age at presentation was 45.5 years (±21.3 years) (n=491), while the mean age at diagnosis was 46.0 years (±21.4 years) ([Figure 2](#f2-opth-9-889){ref-type="fig"}).

[Table 1](#t1-opth-9-889){ref-type="table"} shows the breakdown of our population into four groups.

Univariate analysis
-------------------

### Sex

Of 491 patients, 278 (56.6%) were females, with female: male ratio of 1.3:1.

Diagnoses by sex are given in [Table 2](#t2-opth-9-889){ref-type="table"}. Common diagnoses among females were undifferentiated anterior uveitis, traumatic uveitis, herpetic disease, and human leukocyte antigen (HLA)-B27-associated uveitis. Among males, frequent causes were undifferentiated anterior, post-procedural (following cataract, glaucoma, and cornea surgery or intravitreal injections), trauma, and HLA-B27-related anterior uveitis.

### Ethnicity

A mixed ethnic distribution was seen with 297 (60.5%) Caucasians, 134 (27.3%) African Americans, 48 (9.8%) "Others" (Asian, Indian American, or unidentified), and 12 (2.4%) Hispanics.

The leading cause of uveitis among African American patients was undifferentiated anterior uveitis (29.9%), followed by sarcoidosis (17.2%) ([Table 3](#t3-opth-9-889){ref-type="table"}). The most common causes of uveitis among the 297 Caucasian patients were undifferentiated anterior uveitis (n=63 \[21.2%\]) and trauma (n=35 \[11.8%\]). Sarcoidosis was significantly more common among African Americans than Caucasians (*P*\<0.001), and herpetic anterior uveitis was significantly more common among Caucasians (*P*\<0.001).

Multivariate analysis
---------------------

Multivariate analysis was performed for diagnoses in which a significant difference was found for either race or sex, to assess the contributions of each factor. The data in [Table 4](#t4-opth-9-889){ref-type="table"} were obtained by fitting separate logistic regression models for each disease. Each model used sex and race as predictor variables.

Herpetic anterior uveitis was more common among Caucasians (n=32 \[0.8%\]) than among African Americans (n=2 \[1.5%\]) (sex-adjusted odds ratio: 7.69, 95% confidence interval \[CI\] \[2.12, 50.00\]), while sarcoidosis was more frequent among African Americans (n=23 \[17.2%\]) than among Caucasians (n=9 \[3.0%\]) (sex-adjusted odds ratio: 6.54, 95% CI \[2.98, 15.29\]). Herpetic anterior uveitis was more common among females (n=30 \[10.8%\]) than among males (n=9 \[4.2%\]) (race-adjusted odds ratio: 3.03, 95% CI \[1.32, 7.71\]), while multifocal choroiditis was more common among males (n=8 \[3.8%\]) than among females (n=1 \[0.4%\]) (race-adjusted odds ratio: 9.09, 95% CI \[1.47, 100.00\]).

### Postal codes

Of 1,216 postal codes in VA, we covered 137 (11.3%) ([Figure 3](#f3-opth-9-889){ref-type="fig"}). Among the patients studied, 462 patients resided within VA (473 patients resided in the Mid-Atlantic region), and 27 patients were from other states, most commonly from West VA (seven patients) and Maryland (three patients) ([Table 5](#t5-opth-9-889){ref-type="table"}).[@b15-opth-9-889]

### Visual acuity and intraocular pressure

At patient level (n=458) analysis mean logMAR visual acuities were 0.54±0.74 (Snellen visual acuity 20/70) and 0.52±0.82 (Snellen visual acuity 20/66) at baseline and at the end of the study, respectively (*P*=0.002). At the eye level (n=604), mean logMAR was 0.18 (Snellen visual acuity 20/30) at initial and final follow up. Similarly, at patient level mean logMAR was significantly improved for intermediate uveitis (*P*=0.038). The *P*-value for moderate visual loss and severe visual loss was not significant for anterior, posterior, or panuveitis at the end of the study ([Table 6](#t6-opth-9-889){ref-type="table"}). When analyzed at the eye level, no significant difference was seen for any of the anatomical types of uveitis. Details of visual outcome analysis will follow in a separate paper.

A total of 110 (n=470 \[17.9%\]) of 85 patients presented with ocular hypertension at baseline, while 88 eyes (n=470 \[16.6%\]) of 74 patients had ocular hypertension at the end of the study. Twenty-six eyes (n=470 \[5.3%\]) of 25 patients at baseline presented with hypotension, whereas 28 eyes (n=470 \[6.0%\]) of 26 patients had hypotony at the end of the follow up. Median IOP remained stable with ocular hypertension positively associated with moderate to severe visual loss as compared to normotensive eyes (1.89 times at baseline, 2.62 times at last follow up). Details of IOP outcomes will be included in a separate paper.

### Treatment received

A total of 365 (74.6%) and 133 (27.3%) patients received local or systemic steroids, respectively. Antimetabolites were given to 52 (10.6%) patients, while anti-TNF agents were given in 17 (3.5%) cases.

In all, 116 patients (23.6%) were managed with topical medication; 43 patients (8.8%) underwent glaucoma surgery. One hundred and twenty nine (26.4%) had cataract extraction, and 46 (9.4%) had pars plana vitrectomy. [Table 7](#t7-opth-9-889){ref-type="table"} shows treatment received and complications, like glaucoma, cataract, and pars plana vitrectomy.

### Anatomical localization

The distribution of cases by anatomic site of inflammation is given in [Table 8](#t8-opth-9-889){ref-type="table"}. Anterior uveitis was most common, followed by panuveitis and posterior uveitis.

### Differentiated vs undifferentiated

A total of 335 patients (68.2%) with uveitis met criteria for a specific etiology ([Figure 4](#f4-opth-9-889){ref-type="fig"}). Of these, 63 (18.8%) patients were diagnosed at first consultation, and the remaining 272 (81.2%), were diagnosed on a subsequent visit.

### Clinical classification

Common uveitis diagnoses were undifferentiated anterior uveitis (n=126 \[25.7%\]), followed by trauma (n=60 \[12.2%\]), post-procedural (n=49 \[10.0%\]), herpetic anterior uveitis (n=39 \[7.9%\]), HLA-B27-associated anterior uveitis (n=33 \[6.7%\]), and sarcoidosis (n=33 \[6.7%\]). The relative frequencies of key uveitis diagnoses are shown in [Table 9](#t9-opth-9-889){ref-type="table"}.

Post-procedural uveitis (n=49 \[10%\]) was defined as ocular inflammation following intraocular surgery, laser, or intravitreal injection. Of these, 19 (48.7%) were diagnosed post-cataract extraction and intraocular lens (IOL) placement, four (10.3%) were post-intravitreal injection, six (15.4%) were post-cornea surgery, three (7.7%) were post--laser procedures, six (15.4%) were post-retina surgery, and one (2.6%) was following glaucoma surgery.

A total of 77 patients (16%) had infectious uveitis. The most common infectious etiology was herpetic anterior uveitis (n=39 \[50.6%\]), followed by toxoplasma uveitis (n=14 \[18%\]). The most prevalent viral pathogen was herpes zoster (varicella zoster virus \[VZV\]) (n=21 \[27%\]), followed by herpes simplex virus (HSV) (n=20 \[26%\]). Acute retinal necrosis (ARN) was diagnosed in 14 patients (18%). Aqueous humor was analyzed in all 14 patients with ARN and was positive in seven patients (50%). Of the 77 patients with infectious etiology, 4 (4%) had fungal endophthalmitis, one had syphilitic chorioretinitis (1%), and one had tuberculous uveitis (1%).

Comparison with other studies
-----------------------------

Data on uveitis type, distribution, and diagnosis were compared with those from studies in other centers.[@b5-opth-9-889]--[@b11-opth-9-889] The anatomic distributions of uveitis are shown in [Table 10](#t10-opth-9-889){ref-type="table"}, and the relative frequencies of key uveitis diagnoses are shown in [Table 11](#t11-opth-9-889){ref-type="table"}.

Comparison of anterior, intermediate, and panuveitis with our study is given in [Tables 12](#t12-opth-9-889){ref-type="table"}[](#t13-opth-9-889){ref-type="table"}[](#t14-opth-9-889){ref-type="table"}[15](#t15-opth-9-889){ref-type="table"}.

Discussion
==========

This series reviewed the epidemiologic features of all patients with uveitis seen over a 30-year period at the UVA located in Charlottesville, VA, USA.

Most patients (72.3%) were of working age (18--65 years), and the mean number of visits per patient was eleven visits per year, suggesting that many patients may have been unable to maintain employment while being actively managed. This is consistent with other reports that the estimated economic impact of visual loss among patients younger than 40 years of age in the United States is more than \$38 billion, related to medical care, patient support, and loss of quality of life.[@b16-opth-9-889]

The ratio of females: males was 1.3:1, which is close to the frequency and sex ratio reported in other studies.[@b1-opth-9-889],[@b3-opth-9-889],[@b5-opth-9-889],[@b8-opth-9-889],[@b17-opth-9-889]--[@b20-opth-9-889] For comparison, the female population of VA is 50.8%, with a female:male ratio of 1.03:1.[@b21-opth-9-889] Female patients were predominantly seen in five common diagnostic categories, none of which reached statistical significance on univariate analysis: undifferentiated anterior uveitis, traumatic uveitis, herpetic anterior uveitis, post-procedural, and HLA-B27-associated anterior uveitis. The cause of these types of uveitis being more common in females is not known.

Our study had a higher proportion of African American patients (n=134 \[27%\]) than reported in most other studies (10% in Amsterdam, 13.7% at the University of Louisville, Kentucky, 5.6% in at the University of California, Los Angeles \[UCLA\], and 5.8% at the Massachusetts Eye and Ear Infirmary).[@b1-opth-9-889],[@b5-opth-9-889],[@b9-opth-9-889],[@b28-opth-9-889] Merrill et al[@b5-opth-9-889] reported an African American population of 120 of 385 (31%) at Duke University in the neighboring state of NC. For comparison, Charlottesville, VA has a 69.1% Caucasian and 19.4% African American population. Duke is situated in an area with 42.5% Caucasians and 41.0% African Americans.[@b21-opth-9-889] The percentage of patients with sarcoidosis varies based on region: studies report 5% or less in Portugal, Portland, University of South California, and Iowa; 9% in Amsterdam, and 11% at Duke.[@b5-opth-9-889],[@b10-opth-9-889],[@b22-opth-9-889]--[@b25-opth-9-889] According to Merrill et al the frequencies of sarcoidosis were 25% for African American (30/120) and 5% (14/265) for all non-African American patients.[@b5-opth-9-889] At UVA, the incidence was 17.2% for African American (23/134) and 3% (9/297) for Caucasian patients.

We compared race and sex data for each entity with the race or sex distributions of our uveitis population as a whole. Multivariate analysis revealed significant differences between races for sarcoidosis and herpetic anterior uveitis, as well as significant sex differences for multifocal choroiditis and herpetic anterior uveitis. Herpetic anterior uveitis was significantly more prevalent among Caucasian females and multifocal choroiditis among males. Also, sarcoidosis was significantly more common among African Americans than Caucasians. Factors that influence the occurrence of sarcoidosis manifestations may be familial, genetic, and environmental.[@b39-opth-9-889] Cozier et al reported a higher incidence of sarcoidosis in young African American women. A cohort of 59,000 female participants (1995--2007) between the ages of 21--69 years was surveyed in regards to their health in 13 US states and the District of Colombia. Sarcoidosis can be inherited if either a first- or second-degree relative is affected by the condition.[@b40-opth-9-889]

In a population-based survey in Rochester, MN, conducted over a 10-year period, Darrell et al found that the prevalence for all types of uveitis was 204 cases per 100,000 population. They found 54.1% of all uveitis cases to be anterior, 31.1% to be posterior, and 14.8% to be panuveitis. The annual incidence was 17 new cases per 100,000 population; anterior uveitis occurred four times as frequently as posterior uveitis.[@b26-opth-9-889] McCannel et al reported that most uveitis case series have been reported from tertiary care centers and, therefore, may be affected by referral bias.[@b9-opth-9-889]

Most (32.1%) of our patients had a chronic onset of uveitis. This may be due to referral bias, as acute uveitis was more likely to have been treated by local ophthalmologists and not referred to tertiary care centers.[@b3-opth-9-889] The frequencies for various forms of uveitis in our study were similar to those of many previous studies; for example, reported rates of anterior uveitis in previous studies ranged from 27.8% to 72%.[@b11-opth-9-889],[@b25-opth-9-889]--[@b28-opth-9-889] Some university centers with lower rates of anterior uveitis (22.3%--27.8%) and a higher rate of posterior uveitis (38.4%--48.4%) or panuveitis (38%) than in our study or in other reports suggested that the discrepancy was due to inclusion of all uveitis cases from their retina service.[@b1-opth-9-889],[@b5-opth-9-889],[@b24-opth-9-889]

In our study, the proportion of patients with uveitis for whom a diagnosis could be made was 68.2%. This is higher than rates of diagnosis published by other university referral practice-based investigators, which range from 46% to 67%.[@b3-opth-9-889],[@b23-opth-9-889],[@b25-opth-9-889]--[@b28-opth-9-889] This could be explained by better diagnostic techniques over the latter period of our study. Also, definitive diagnosis was often made during long-term follow up rather than at the initial visit, which has been emphasized by a previous study.[@b3-opth-9-889]

Comparisons with surveys undertaken in uveitis clinics elsewhere in the world often present great contrasts in the numbers of patients affected within diagnostic categories.[@b3-opth-9-889],[@b5-opth-9-889],[@b16-opth-9-889],[@b18-opth-9-889],[@b23-opth-9-889],[@b29-opth-9-889]--[@b37-opth-9-889] With a combination of different uveitis classification criteria, the most common uveitis diagnoses in our analysis were undifferentiated anterior uveitis (25.4%), trauma (12.2%), post-procedural (9.9%), herpetic anterior uveitis (7.9%), HLA-B27 anterior uveitis (6.7%), and sarcoidosis (6.7%).

For undifferentiated anterior uveitis, Perkins and Folk investigated the influence of geographic factors on uveitis through the examination of two populations, in London and Iowa (IA). The London population consisted of an urban community, whereas the IA study involved a rural region. They showed no correlation between geographic factors and the type of uveitis manifested. However, the results suggest that genetics has a stronger association than geographic factors.[@b10-opth-9-889]

The most common type of infectious uveitis seen over the study period was herpetic anterior uveitis secondary to VZV or HSV, which is comparable with findings of other American epidemiologic studies.[@b3-opth-9-889],[@b11-opth-9-889] Ocular toxoplasmosis and ARN were also common causes of infectious uveitis.

[Table 12](#t12-opth-9-889){ref-type="table"} shows the types of anterior uveitis seen in our study population in comparison with other studies.[@b1-opth-9-889],[@b3-opth-9-889],[@b5-opth-9-889],[@b8-opth-9-889]--[@b10-opth-9-889],[@b11-opth-9-889],[@b25-opth-9-889] We had a large population of patients with traumatic uveitis, which could be relevant to the subset of student population and outdoor sports activities at the UVA. Macewen reported that increasing time available for leisure activities has been parallel to an increase in sport-associated eye trauma.[@b45-opth-9-889] Traumatic uveitis has been mentioned in only few of the previous studies. The Manchester study included two cases of traumatic anterior uveitis, whereas a UCLA study had 4.8% of their community-based cases in this category.[@b8-opth-9-889],[@b9-opth-9-889] It has been postulated that the rate at which traumatic anterior uveitis was reported may be artificially high, as trauma may bring patients with preexistent uveitis to the eye clinics.[@b9-opth-9-889] Also, patients who report to the emergency room at our hospital are commonly evaluated in the eye clinic as well. In contrast to other studies, we classified all uveitis following ophthalmic surgery, intravitreal injection, or laser procedure as post-procedural uveitis.[@b5-opth-9-889],[@b8-opth-9-889],[@b9-opth-9-889]

Intermediate uveitis is most often undifferentiated.[@b41-opth-9-889] However, specific systemic syndromes have also been associated with this form of inflammatory eye disease.[@b42-opth-9-889] In our study, the most common systemic disease association was sarcoidosis, as was reported by Rodriguez et al, Merrill et al, Henderly et al and also in studies conducted in Rotterdam (16% \[n=68\]) and Amsterdam (9% \[n=76\])[@b3-opth-9-889],[@b5-opth-9-889],[@b22-opth-9-889],[@b25-opth-9-889],[@b28-opth-9-889] ([Table 11](#t11-opth-9-889){ref-type="table"}).

Our study and others support toxoplasmosis as the most common cause of posterior uveitis.[@b3-opth-9-889],[@b10-opth-9-889],[@b25-opth-9-889],[@b43-opth-9-889] Multifocal choroiditis and undifferentiated uveitis were the next common entities in our study. Retinal vasculitis was mentioned as a causative group in previous epidemiologic studies.[@b5-opth-9-889],[@b38-opth-9-889],[@b44-opth-9-889] In our patients, retinal vasculitis, a descriptive diagnosis, was seen in many patients with sarcoidosis, Behcet's, Birdshot chorioretinopathy, and Eales disease.

These differences may reflect changes in etiologies over time, as well as better understanding of different uveitic entities, evolution of better diagnostic techniques, and, maybe, real change in disease frequency. More frequent use of PCR on aqueous and vitreous samples, in conjunction with the latest diagnostic tools of ultrawide field imaging and high-definition OCT permit improved characterization of uveitis and may thereby diminish the number of undifferentiated cases of posterior and panuveitis.

Limitations
-----------

Our uveitis epidemiologic report is retrospective in nature and was largely based on patients referred to our tertiary care center, and therefore, referral bias may exist. Beside true geographic, genetic, environmental, and ethnic differences, other factors may influence the diagnostic variability between different epidemiological studies. Differences in the diagnostic approach of ophthalmologists, availability of uveitis-trained faculty, accessibility to newer diagnostic techniques, and the evolution of diagnostic criteria employed by individual authors are among such factors. Nevertheless, reporting the frequency of various diseases in our area provides a more complete understanding of uveitis in the United States and may help inform future studies.

Conclusion
==========

In summary, we studied a well-defined population of 491 patients at the UVA Eye Center. To our knowledge, this study of uveitis demographic analysis is unique, as it is the first to be conducted in central Virginia. Over the period of this study, Caucasian patients were more frequently seen than non-Caucasians, but African Americans constituted a considerable size of study population. The frequencies of anterior, intermediate, posterior, and panuveitis were within the range reported by other university-based reports. However, unlike other studies, we had more cases of traumatic and post-procedural uveitis. Common uveitis types observed were undifferentiated anterior, traumatic, post-procedural, herpetic disease, HLA-B27 disease, and sarcoidosis. Importantly, mean overall visual acuity remained stable for the cohort from initial to final visit, with the majority receiving topical corticosteroids, confirming that therapeutic interventions are effective.
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###### 

Age groups

  Age group (years)[\*](#tfn1-opth-9-889){ref-type="table-fn"}   Patients, n   Percentage
  -------------------------------------------------------------- ------------- ------------
  \<18                                                           39            7.9
  18--35                                                         129           26.3
  18--65                                                         355           72.3
  \>65                                                           97            19.8

**Notes:**

The groups were defined as: \<18 years = pediatric group; 18--35 years = young adults; 18--65 years = working-age group; \>65 years = older-age group.

###### 

Distribution of diagnoses by sex

  ------------------------------------------------------------------------------------------------------------------------
  Diagnosis                             Female\       Male\         *P*-value[\*](#tfn2-opth-9-889){ref-type="table-fn"}
                                        n (%)         n (%)         
  ------------------------------------- ------------- ------------- ------------------------------------------------------
  Anterior uveitis, undifferentiated    73 (26.3)     53 (24.9)     0.755

  Trauma                                40 (14.3)     20 (9.4)      0.098

  Viral                                                             

   Herpetic anterior uveitis            30 (10.8)     9 (4.2)       0.011

   Acute retinal necrosis               9 (3.2)       4 (1.9)       0.408

   CMV uveitis                          2 (0.7)       2 (0.9)       1.000

   Herpetic panuveitis                  1 (0.4)       0 (0.0)       1.000

  Post-procedural uveitis               21 (7.6)      28 (13.1)     0.048

  Anterior uveitis HLA-B27              18 (6.5)      15 (7.0)      0.857

  Sarcoidosis                           17 (6.1)      16 (7.5)      0.588

  Intermediate uveitis                  11 (4.0)      8 (3.8)       1.000

  Panuveitis, undifferentiated          11 (4.0)      12 (5.6)      0.397

  Others                                8 (2.9)       11 (5.2)      0.240

  Infectious, nonviral                                              

   Toxoplasma                           8 (2.9)       6 (2.8)       1.000

   Fungal                               3 (1.1)       1 (0.5)       0.637

   Syphilis                             1 (0.4)       0 (0.0)       1.000

   Tuberculosis                         1 (0.4)       0 (0.0)       1.000

  Posterior uveitis, undifferentiated   6 (2.2)       3 (1.4)       0.738

  White dot syndrome                                                

   Birdshot                             5 (1.8)       2 (0.9)       0.704

   MEWDS                                2 (0.7)       1 (0.5)       1.000

   Multifocal choroiditis               1 (0.4)       8 (3.8)       0.012

   APMPPE                               1 (0.4)       3 (1.4)       0.321

   Serpiginous                          1 (0.4)       2 (0.9)       0.582

  Seronegative SpA                                                  

   Ankylosing spondylitis               2 (0.7)       3 (1.4)       0.657

   Crohn's disease                      2 (0.7)       2 (0.9)       1.000

   Ulcerative colitis                   1 (0.4)       1 (0.5)       1.000

   Reactive arthritis                   1 (0.4)       0 (0.0)       1.000

   Psoriatic arthritis                  0 (0.0)       1 (0.5)       0.434

  Eales disease                         1 (0.4)       0 (0.0)       1.000

  Collagen vascular disease                                         

   Polyarteritis nodosa                 1 (0.4)       0 (0.0)       1.000

   Granulomatosis with polyangiitis     0 (0.0)       1 (0.5)       0.434

  Total                                 279 (100.0)   214 (100.0)   0.066[\#](#tfn3-opth-9-889){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------

**Notes:**

Fisher's exact test on 2×2 table, eg, female vs male compared on sarcoidosis vs all other diagnoses.

Fisher's exact test applied to entire table, using Monte Carlo sampling (*P*=0.085).

**Abbreviations:** APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.

###### 

Distribution of diagnoses by race

  ------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis                                   African American\   Caucasian\    *P*-value[\*](#tfn5-opth-9-889){ref-type="table-fn"}
                                              n (%)               n (%)         
  ------------------------------------------- ------------------- ------------- ------------------------------------------------------
  Viral                                                                         

   Herpetic anterior uveitis                  2 (1.5)             32 (10.8)     \<0.001

   Acute retinal necrosis                     5 (3.7)             8 (2.7)       0.553

   CMV uveitis                                1 (0.7)             3 (1.0)       1.000

   Herpetic panuveitis                        0 (0.0)             1 (0.3)       1.000

  Sarcoidosis                                 23 (17.2)           9 (3.0)       \<0.001

  Anterior uveitis, undifferentiated          40 (29.9)           63 (21.2)     0.067

  Trauma                                      22 (16.4)           35 (11.8)     0.219

  Post-procedural                             14 (10.4)           27 (9.1)      0.723

  Anterior uveitis HLA-B27                    8 (6.0)             22 (7.4)      0.686

  Others                                      2 (1.5)             15 (5.1)      0.108

  Intermediate uveitis                        3 (2.2)             14 (4.7)      0.291

  Panuveitis, undifferentiated                7 (5.2)             13 (4.4)      0.805

  Infectious (bacterial, fungal, parasitic)                                     

   Toxoplasma                                 1 (0.7)             10 (3.4)      0.185

   Fungal                                     0 (0.0)             4 (1.3)       0.315

   Syphilis                                   0 (0.0)             1 (0.3)       1.000

   Tuberculosis                               0 (0.0)             0 (0.0)       1.000

  Posterior uveitis, undifferentiated         2 (1.5)             6 (2.0)       1.000

  White dot syndrome                                                            

   Multifocal choroiditis                     3 (2.2)             5 (1.7)       0.708

   Birdshot                                   0 (0.0)             5 (1.7)       0.330

   APMPPE                                     0 (0.0)             4 (1.3)       0.315

   Serpiginous                                0 (0.0)             3 (1.0)       0.556

   MEWDS                                      0 (0.0)             2 (0.7)       1.000

  Seronegative SpA                                                              

   Ankylosing spondylitis                     0 (0.0)             5 (1.7)       0.330

   Crohn's disease                            0 (0.0)             4 (1.3)       0.315

   Reactive arthritis                         0 (0.0)             1 (0.3)       1.000

   Ulcerative colitis                         0 (0.0)             1 (0.3)       1.000

   Psoriatic arthritis                        0 (0.0)             1 (0.3)       1.000

  Collagen vascular disease                                                     

   Granulomatosis with polyangiitis           0 (0.0)             1 (0.3)       1.000

   Polyarteritis nodosa                       0 (0.0)             1 (0.3)       1.000

  Fuch's iridocyclitis                        0 (0.0)             1 (0.3)       1.000

  Eales disease                               1 (0.8)             0 (0.0)       0.311

  Total                                       134 (100.0)         297 (100.0)   \<0.001[†](#tfn6-opth-9-889){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Fisher's exact test on 2×2 table, eg, African American vs Caucasian compared on sarcoidosis vs all other diagnoses.

Fisher's exact test applied to entire table, using Monte Carlo sampling.

**Abbreviations:** APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegaovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.

###### 

Multivariate analysis for race and sex

  Diagnosis                            Odds ratio (95% confidence interval)[\*](#tfn8-opth-9-889){ref-type="table-fn"}   
  ------------------------------------ --------------------------------------------------------------------------------- ---------------------
  Sarcoidosis                          6.54 \[2.98, 15.29\]                                                              0.89 \[0.42, 1.91\]
  Anterior uveitis, undifferentiated   1.58 \[0.99, 2.51\]                                                               1.02 \[0.65, 1.60\]
  Herpetic anterior uveitis            0.13 \[0.02, 0.47\]                                                               3.03 \[1.32, 7.71\]
  Multifocal choroiditis               1.24 \[0.24, 5.52\]                                                               0.11 \[0.01, 0.68\]
  Trauma                               1.51 \[0.83, 2.69\]                                                               1.76 \[0.97, 3.25\]
  Post-procedural                      1.14 \[0.56, 2.24\]                                                               0.55 \[0.29, 1.06\]

**Notes:**

Odds ratios were computed via exact logistic regression. The odds ratios are \>1 when African Americans or females are more likely to have the disease. The odds ratios are statistically significant if the 95% confidence interval does not include 1.

###### 

States of residence for patients seeking care at the University of Virginia

  State   Number of patients
  ------- --------------------
  AL      1
  CA      1
  FL      2
  GA      2
  MD      3
  MI      2
  NC      1
  NM      1
  NY      1
  OR      1
  SC      2
  TN      1
  VA      462
  WA      1
  WV      7
  WY      1

**Abbreviations:** AL, Alabama; CA, California; FL, Florida; GA, Georgia; MD, Maryland; MI, Michigan; NC, North Carolina; NM, New Mexico; NY, New York; OR, Oregon; SC, South Carolina; TN, Tennessee; VA, Virginia; WA, Washington; WV, West Virginia; WY, Wyoming.

###### 

Change in visual acuity

  Overall                                                                                          
  --------------------------------------------------------------------- ----- ------ ------ ------ ------
  Initial logMAR                                                        458   0.54   0.74   0.03   0.3
  Final logMAR *P*=0.002[\*](#tfn10-opth-9-889){ref-type="table-fn"}    458   0.52   0.82   0.04   0.18
  Anterior uveitis                                                                                 
   Initial logMAR                                                       308   0.44   0.63   0.04   0.18
   Final logMAR *P*=0.058[\*](#tfn10-opth-9-889){ref-type="table-fn"}   308   0.45   0.78   0.04   0.16
  Intermediate uveitis                                                                             
   Initial logMAR                                                       25    0.61   0.83   0.17   0.3
   Final logMAR *P*=0.038[\*](#tfn10-opth-9-889){ref-type="table-fn"}   25    0.27   0.35   0.07   0.14
  Posterior uveitis                                                                                
   Initial logMAR                                                       64    1.07   1.05   0.13   0.63
   Final logMAR *P*=0.197[\*](#tfn10-opth-9-889){ref-type="table-fn"}   64    0.99   1.05   0.13   0.53
  Panuveitis                                                                                       
   Initial logMAR                                                       57    0.43   0.4    0.05   0.39
   Final logMAR *P*=0.216[\*](#tfn10-opth-9-889){ref-type="table-fn"}   57    0.45   0.63   0.08   0.25

**Notes:**

Wilcoxon rank sum test, analysis done at patient level.

**Abbreviations:** SD, standard deviation; SE, standard error of the mean.

###### 

Ophthalmic management and interventions

  Treatment/intervention       Number (%)
  ---------------------------- -------------
  Local steroids               365 (74.6%)
  Systemic steroids            133 (27.3%)
  Anti-TNF agents              17 (3.5%)
  Antimetabolites              52 (10.6%)
  Intravitreal injection       54 (11.0%)
  Sub-Tenon injection          23 (4.7%)
  Glaucoma topical treatment   116 (23.6%)
  Glaucoma surgery             43 (8.8%)
  Cataract surgery             129 (26.4%)
  Pars plana vitrectomy        46 (9.4%)

**Abbreviation:** TNF, tumor necrosis factor.

###### 

Anatomical classification

  Definition             Number   Percentage   Number bilateral   Number unilateral
  ---------------------- -------- ------------ ------------------ -------------------
  Anterior uveitis       332      67.6         75                 257
  Intermediate uveitis   26       5.3          19                 7
  Posterior uveitis      62       12.6         32                 30
  Panuveitis             71       14.5         44                 27

###### 

Uveitis diagnoses at University of Virginia

  Diagnosis                             Patients, n   Percentage
  ------------------------------------- ------------- ------------
  Anterior uveitis, undifferentiated    126           25.7
  Trauma                                60            12.2
  Post-procedural                       49            10.0
  Viral                                               
   Acute retinal necrosis               13            2.7
   Herpetic anterior uveitis            39            7.9
   CMV uveitis                          4             0.8
   Herpetic panuveitis                  1             0.2
  Sarcoidosis                           33            6.7
  HLA-B27 anterior uveitis              33            6.7
  Fuch's iridocyclitis                  1             0.2
  Intermediate uveitis                  26            5.3
  Panuveitis, undifferentiated          23            4.7
  Infectious                                          
   Toxoplasma                           14            2.9
   Syphilis                             1             0.2
   Tuberculosis                         1             0.2
   Fungal                               4             0.8
  Posterior uveitis, undifferentiated   9             1.8
  White dot syndrome                                  
   Multifocal choroiditis               9             1.8
   Birdshot                             7             1.4
   APMPPE                               4             0.8
   Serpiginous                          3             0.6
   MEWDS                                3             0.6
  Eales disease                         1             0.2
  Collagen vascular disease                           
   Granulomatosis with polyangiitis     1             0.2
   Polyarteritis nodosa                 1             0.2
  Seronegative SpA                                    
   Reactive arthritis                   1             0.2
   Ankylosing spondylitis               5             1.0
   Crohn's disease                      4             0.8
   Ulcerative colitis                   2             0.4
   Psoriatic arthritis                  1             0.2
  Others                                19            3.9
  Total                                 491           100.0

**Abbreviations:** APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; HLA, human leukocyte antigen; MEWDS, multiple evanescent white dot syndrome; seronegative SpA, seronegative spondyloarthropathy.

###### 

Multicenter comparison of anatomic location of uveitis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             UVA          Centers                                                                                                   
  -------------------------- ------------ ------------ ------------ ------------ ------------- ------------ ------------ ------------ ------------- ----------------
  Time period                1984--2014   1982--1992   1989--1994   1956--1960   1991--1994    2006--2007   1990--1995   1991--2013   --            2006--2010

  Patients (N)               491          1,237        385          172          213           217,061      853          3,301        2,693 (ME)\   43 (FN)\
                                                                                                                                      4,379 (EU)    45 (control)

  Anterior uveitis (%)       67.6         51.6         25           60.0 (I)\    90.6 (CBP)\   72           22.3         46           49.6 (ME)\    26.0 (FN)\
                                                                    63.0 (L)     60.6 (URP)                                           51.3 (EU)     73.0 (control)

  Posterior uveitis (%)      12.6         17.4         24           29 (I)\      4.7 (CBP)\    29           48.4         21.8         15.5 (ME)\    7.0 (FN)\
                                                                    19 (L)       14.6 (URP)                                           23.7 (EU)     2.0 (control)

  Intermediate uveitis (%)   5.3          13           12           6            1.4 (CBP)\    6            10.9         11.1         10.3 (ME)\    0.0 (FN)\
                                                                                 12.2 (URP)                                           9.1 (EU)      9.0 (control)

  Panuveitis (%)             14.5         16           38           10.0 (I)\    1.4 (CBP)\    21           18.4         21.1         24.9 (ME)\    67.0 (FN)\
                                                                    18.0 (L)     9.4 (URP)                                            15.9 (EU)     16.0 (control)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

IA and UCLA frequencies extrapolated from data, as different localization systems used.

**Abbreviations:** UVA, University of Virginia; MEEI, Massachusetts Eye and Ear Infirmary; Duke, Duke University; IA, University of Iowa; UCLA, University of California at Los Angeles; USC, University of Southern California; KY, University of Louisville, Kentucky; REH, The Royal Eye Hospital, Manchester, UK; SBU, Shahid Beheshti University of Medical Sciences, Tehran, Iran; UM, University of Manitoba, Winnipeg, Canada; ME, Middle East; EU, Europe; FN, First Nation; L, London; I, Iowa; CBP, Community Based Practice; URP, University Referral Practice.

###### 

Relative frequencies of key uveitis diagnoses

                                           UVA          Centers                                                                       
  ---------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Time period                              1984--2014   1982--1992   1989--1994   1956--1960   1991--1994   2006--2007   1990--1995   1991--2013
  Patients, n                              491          1,237        385          172          213          217,061      853          3,301
  Sarcoidosis, %                           6.7          9.6          11           5            0.8          2            2.2          9.7
  Granulomatosis with polyangiitis, %      0.2                                                                                        
  Polyarteritis nodosa, %                  0.2          0.2                                                                           
  Anterior uveitis, undifferentiated, %    25.7         37.8         12           60           30.5                      54.2         7
  Intermediate, %                          3.9                       12           6            12.2                      78.7         
  Panuveitis, undifferentiated, %          4.7          22.2         17                        40                        30.9         6.6
  Posterior uveitis, undifferentiated, %   1.8          13.3         2            17                                     19.3         
  Toxoplasma, %                            2.9          4.8          10           9                         4            3.9          6.9
  Syphilis, %                              0.2          1.7          0.5          1                                                   
  Tuberculosis, %                          0.2          0.6          0.5                                    0.4                       
  Fungal, %                                0.8          0.3                                                                           
  Reactive arthritis, %                    0.2                                                              1                         
  Ankylosing spondylitis, %                1            3.8          2                                      3                         
  Crohn's disease, %                       0.8          0.7                                                                           
  Ulcerative colitis, %                    0.4          0.5                                                                           
  Psoriatic arthritis, %                   0.2                                                                                        
  Acute retinal necrosis, %                2.7                       2                                                                
  Herpetic anterior uveitis, %             7.9          9.7          3                                                                
  CMV uveitis, %                           0.8          2.2                                                              15.1         
  Herpetic panuveitis, %                   0.2                                                                                        
  Multifocal choroiditis, %                1.8                       6                         6.5                       4.9          
  Birdshot, %                              1.4                       0.78                      6.5          1            1.6          
  APMPPE, %                                0.8                       0.5                                                              
  Serpiginous, %                           0.6                                                 3.2                       1.9          
  MEWDS, %                                 0.6                                                              0.4                       
  Trauma, %                                12.2                                                                                       
  Post-procedural, %                       10                                                                                         
  Fuch's iridocyclitis, %                  0.2                       2                                      1                         11.5
  Eales disease, %                         0.2                                                                                        
  Anterior uveitis HLA-B27, %              6.7          31.3         19                        17.8                      8.4          3.6
  Others, %                                3.9                                                                                        

**Notes:**

IA and UCLA frequencies extrapolated from data, as different localization systems were used.

**Abbreviations:** APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; Duke, Duke University; HLA, human leukocyte antigen; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; MEWDS, multiple evanescent white dot syndrome; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.

###### 

Anterior uveitis diagnoses

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                       UVA\        Duke[@b5-opth-9-889]\                           MEEI[@b3-opth-9-889]\                           USC[@b26-opth-9-889]\                           UCLA[\*\*](#tfn20-opth-9-889){ref-type="table-fn"}[@b9-opth-9-889]\   KY[@b1-opth-9-889]\                             IA[\*\*](#tfn20-opth-9-889){ref-type="table-fn"}[@b10-opth-9-889]\   REH[\*\*](#tfn20-opth-9-889){ref-type="table-fn"}[@b8-opth-9-889] n=3,301\
                                       n=332\      n=97\                                           n=637\                                          n=167\                                          n=129\                                                                n=190\                                          n=104\                                                               %[\*](#tfn19-opth-9-889){ref-type="table-fn"}
                                       n, (%)      %[\*](#tfn19-opth-9-889){ref-type="table-fn"}   %[\*](#tfn19-opth-9-889){ref-type="table-fn"}   %[\*](#tfn19-opth-9-889){ref-type="table-fn"}   %[\*](#tfn19-opth-9-889){ref-type="table-fn"}                         %[\*](#tfn19-opth-9-889){ref-type="table-fn"}   %[\*](#tfn19-opth-9-889){ref-type="table-fn"}                        
  ------------------------------------ ----------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------
  Undifferentiated                     126 (38)    49                                              37.8                                            12.1                                            50.5                                                                  54.2                                            60                                                                   12.3

  Trauma                               59 (17.8)                                                                                                   0.8                                                                                                                   2.7                                                                                                                  

  Herpetic uveitis                     39 (11.7)   3.0                                             9.7                                             9.0                                                                                                                   2.2                                                                                                                  1.7

  Post-procedural                      36 (10.5)                                                                                                                                                                                                                                                                                                                                              

  HLA-B27                              33 (9.9)    19.0                                            6.4                                             3.0                                             17.8                                                                  8.4                                                                                                                  4.5

  Sarcoidosis                          19 (5.7)    3.0                                             5.8                                                                                                                                                                   1.2                                             11.0                                                                 2.39

  Ankylosing spondylitis               4 (1.2)     9.0                                             7.4                                             1.5                                                                                                                   4.7                                             13.0                                                                 

  IBD                                  4 (1.2)     1.0                                             2.4                                             0.7                                                                                                                                                                   7.0                                                                  0.96

  Reactive                             1 (0.3)     3.0                                             4.0                                             1.0                                                                                                                                                                   12.0                                                                 0.66

  Psoriatic arthritis                  1 (0.3)                                                     0.8                                                                                                                                                                                                                                                                                        0.57

  Fuch's heterochromic iridocyclitis   1 (0.3)     7.0                                             5.0                                             1.8                                                                                                                   2.2                                             39.0                                                                 11.5

  Granulomatosis with polyangiitis     1 (0.3)                                                     0.5                                                                                                                                                                                                                                                                                        

  Others                               8 (2.7)                                                                                                                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Others included: TINU (3), rheumatoid arthritis (1), juvenile rheumatoid arthritis (1), multiple sclerosis (1), and Posner--Schlossman syndrome (2).

All values given as percentage only.

UCLA, IA, and REH values extrapolated from given data.

**Abbreviations:** Duke, Duke University; HLA, human leukocyte antigen; IA, University of Iowa; IBD, Inflammatory bowel disease; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; TINU, tubulointerstitial nephritis and uveitis; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.

###### 

Intermediate uveitis diagnoses

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           UVA\       Duke[@b5-opth-9-889]\                              MEEI[@b3-opth-9-889]\                               USC[@b26-opth-9-889]\                              UCLA[\*\*](#tfn23-opth-9-889){ref-type="table-fn"}[@b9-opth-9-889]\   KY[@b1-opth-9-889]\   IA[\*\*](#tfn23-opth-9-889){ref-type="table-fn"}[@b10-opth-9-889]\   REH[\*\*](#tfn23-opth-9-889){ref-type="table-fn"}[@b8-opth-9-889]\
                           n=26 (%)   n=47[\*](#tfn22-opth-9-889){ref-type="table-fn"}   n=162[\*](#tfn22-opth-9-889){ref-type="table-fn"}   n=92[\*](#tfn22-opth-9-889){ref-type="table-fn"}   n=26[\*](#tfn22-opth-9-889){ref-type="table-fn"}                      n=94                  n=52[\*](#tfn22-opth-9-889){ref-type="table-fn"}                     n=3,301[\*](#tfn22-opth-9-889){ref-type="table-fn"}
  ------------------------ ---------- -------------------------------------------------- --------------------------------------------------- -------------------------------------------------- --------------------------------------------------------------------- --------------------- -------------------------------------------------------------------- --------------------------------------------------------------------
  Undifferentiated         20 (77)    98                                                 69.1                                                100                                                30.8                                                                  94.7                  40.0                                                                 7.8

  Sarcoidosis              3 (11.5)   2.0                                                22.2                                                                                                   0                                                                                                                                                                1.75

  Multiple sclerosis       2 (3.8)                                                       8.0                                                                                                    0                                                                     2.1                                                                                        0.54

  Ankylosing spondylitis   1 (3.8)                                                                                                                                                                                                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

All values given as percentage only.

UCLA, IA, and REH values extrapolated from given data.

**Abbreviations:** Duke, Duke University; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.

###### 

Posterior uveitis diagnoses

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           UVA\        Duke[@b5-opth-9-889]\                              MEEI[@b3-opth-9-889]\                               USC[@b26-opth-9-889]\                               UCLA[\*\*](#tfn27-opth-9-889){ref-type="table-fn"}[@b9-opth-9-889]\   KY[@b1-opth-9-889]\                                 IA[\*\*](#tfn27-opth-9-889){ref-type="table-fn"}[@b10-opth-9-889]\   REH[\*\*](#tfn27-opth-9-889){ref-type="table-fn"}[@b8-opth-9-889]\
                           n=62 (%)    n=93[\*](#tfn26-opth-9-889){ref-type="table-fn"}   n=240[\*](#tfn26-opth-9-889){ref-type="table-fn"}   n=230[\*](#tfn26-opth-9-889){ref-type="table-fn"}   n=31[\*](#tfn26-opth-9-889){ref-type="table-fn"}                      n=414[\*](#tfn26-opth-9-889){ref-type="table-fn"}   n=52[\*](#tfn26-opth-9-889){ref-type="table-fn"}                     n=3,301[\*](#tfn26-opth-9-889){ref-type="table-fn"}
  ------------------------ ----------- -------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------
  Toxoplasma               11 (17.7)   42.0                                               24.6                                                9.0                                                 35.5                                                                  7.7                                                 65.0                                                                 6.9

  Multifocal choroiditis   9 (14.5)                                                                                                           18.0                                                9.7                                                                   10.1                                                                                                                     0.8

  Undifferentiated         9 (14.5)    9                                                  13.3                                                15.0                                                16.2                                                                  19.3                                                48.0                                                                 

  Acute retinal necrosis   4 (6.5)     9                                                  5.5                                                                                                                                                                           2.7                                                                                                                      0.2

  Birdshot                 7 (11.3)    3                                                  7.9                                                 3.0                                                 6.5                                                                   3.4                                                                                                                      1.09

  MEWDS                    3 (4.8)                                                        1.25                                                                                                                                                                          1.2                                                                                                                      0.4

  APMPPE                   3 (4.8)     2                                                  2.0                                                                                                                                                                                                                                                                                                    

  Serpiginous              3 (4.8)                                                        1.6                                                 5.0                                                 3.2                                                                   3.9                                                                                                                      0.3

  Sarcoidosis              2 (3.2)                                                        7.5                                                 3.9                                                                                                                       2.2                                                 4.0                                                                  2.9

  CMV                      2 (3.2)                                                        11.6                                                7.0                                                                                                                       31.2                                                                                                                     0.7

  Syphilis                 1 (1.6)                                                        2.0                                                                                                                                                                                                                               4.0                                                                  

  Polyarteritis nodosa     1 (1.6)                                                        0.83                                                                                                                                                                                                                                                                                                   

  Eales disease            1 (1.6)                                                                                                                                                                                                                                                                                                                                                               

  Others                   2 (3.2)                                                                                                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Others included: IRVAN (2).

All values given as percentage only.

UCLA, IA, and REH values extrapolated from given data.

**Abbreviations:** APMPPE, acute posterior multifocal placoid pigment epitheliopathy; CMV, cytomegalovirus; Duke, Duke University; IA, University of Iowa; IRVAN, idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; MEWDS, multiple evanescent white dot syndrome; REH, Royal Eye Hospital, Manchester, UK; USC, University of Southern California; UCLA, University of California at Los Angeles; UVA, University of Virginia.

###### 

Panuveitis diagnoses

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           UVA\        Duke[@b5-opth-9-889]\                               MEEI[@b3-opth-9-889]\                               USC[@b26-opth-9-889]\                               UCLA[\*\*](#tfn31-opth-9-889){ref-type="table-fn"}[@b9-opth-9-889]\   KY[@b1-opth-9-889]\                                 IA[\*\*](#tfn31-opth-9-889){ref-type="table-fn"}[@b10-opth-9-889]\   REH[\*\*](#tfn31-opth-9-889){ref-type="table-fn"}[@b8-opth-9-889]\
                           n=71 (%)    n=148[\*](#tfn30-opth-9-889){ref-type="table-fn"}   n=198[\*](#tfn30-opth-9-889){ref-type="table-fn"}   n=111[\*](#tfn30-opth-9-889){ref-type="table-fn"}   n=20[\*](#tfn30-opth-9-889){ref-type="table-fn"}                      n=155[\*](#tfn30-opth-9-889){ref-type="table-fn"}   n=18[\*](#tfn30-opth-9-889){ref-type="table-fn"}                     n=3,301[\*](#tfn30-opth-9-889){ref-type="table-fn"}
  ------------------------ ----------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------
  Undifferentiated         23 (32.4)   43.0                                                22.2                                                45.0                                                18.7                                                                  30.9                                                27.0                                                                 

  Post-procedural          13 (18.3)                                                                                                                                                                                                                                                                                                                                                              

  Acute retinal necrosis   9 (12.7)                                                                                                            18.0                                                                                                                      1.3                                                                                                                      

  Sarcoidosis              9 (12.7)    27.0                                                14.1                                                21.0                                                2.3                                                                   4.5                                                 28.0                                                                 2.99

  Toxoplasma               3 (4.2)                                                                                                                                                                                                                                                                                                                                                                

  Fungal                   3 (4.2)                                                         2.0                                                                                                                                                                                                                                                                                                    

  Herpetic uveitis         2 (2.8)                                                                                                                                                                                                                                                                                                                                                                0.01

  Trauma                   1 (1.4)                                                                                                                                                                                                                                                                                                                                                                

  Tuberculosis             1 (1.4)     1.0                                                 2.0                                                                                                                                                                                                                                                                                                    

  Others                   4 (5.6)                                                                                                                                                                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Others included: Behcet's disease (1), Vogt--Koyanagi--Harada disease (1), juvenile rheumatoid arthritis (1).

All values given as percentage only.

UCLA, IA, and REH values extrapolated from given data.

**Abbreviations:** Duke, Duke University; IA, University of Iowa; KY, University of Louisville, Kentucky; MEEI, Massachusetts Eye and Ear Infirmary; REH, Royal Eye Hospital, Manchester, UK; UCLA, University of California at Los Angeles; USC, University of Southern California; UVA, University of Virginia.
